ストックスクリーナーアプリを入手
15.97
0.98%
0.16
前日終値:
$15.81
開ける：
$15.98
24時間の取引高:
431.87K
Relative Volume:
0.41
時価総額：
$798.76M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-4.3279
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
+1.11%
1か月 パフォーマンス:
+33.82%
6か月 パフォーマンス:
+82.46%
1年 パフォーマンス:
+3.74%
1日の値動き範囲:
$15.83
$16.09
1週間の範囲:
$15.20
$16.23
52週間の値動き範囲:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.99 | 757.80M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.00 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.62 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.60 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.93 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
What drives KalVista Pharmaceuticals Inc. stock priceOutstanding yields - jammulinksnews.com
What analysts say about KalVista Pharmaceuticals Inc. stockSuperior trading gains - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
Kalvista's Ekterly OK'd as on-demand HAE swelling attack treatment in UK - Angioedema News
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria
KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest
Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks
Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia
Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace
KalVista price target raised to $27 from $19 at Citizens JMP - MSN
KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins By Investing.com - Investing.com South Africa
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria
KalVista Shares Fall After Fiscal 2025 Results - MarketScreener
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener
Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30Earnings Summary - TradingView
Kalvista Pharmaceuticals IncFDA approves Kalvista's Ekterly for hereditary angioedema - MarketScreener
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
4.20%
0.52%
大文字化:
|
ボリューム (24 時間):